Discover Oncology (Jul 2022)

LncRNAs as epigenetic regulators of epithelial to mesenchymal transition in pancreatic cancer

  • Yan Ma,
  • Yang Di,
  • Qiuyue Li,
  • Qilin Zhan,
  • Xiaomeng He,
  • Shanshan Liu,
  • Heng Zou,
  • Christopher Corpe,
  • Litian Chen,
  • Jin Wang

DOI
https://doi.org/10.1007/s12672-022-00522-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Pancreatic cancer is the leading cause of cancer-related mortality because of tumor metastasis. Activation of the epithelial-to-mesenchymal transition (EMT) pathway has been confirmed to be an important driver of pancreatic cancer progression from initiation to metastasis. Long noncoding RNAs (lncRNAs) have been reported to exert essential physiological functions in pancreatic cancer progression by regulating the EMT program. In this review, we have summarized the role of EMT-related lncRNAs in human pancreatic cancer and the potential molecular mechanisms by which lncRNAs can be vital epigenetic regulators of epithelial to mesenchymal transition. Specifically, EMT-activating transcription factors (EMT-TFs) regulate EMT via TGF-β/Smad, Wnt/β-catenin, and JAK/STAT pathways. In addition, the interaction between lncRNAs and HIF-1α and m6A RNA methylation also have an impact on tumor metastasis and EMT in pancreatic cancer. This review will provide insights into lncRNAs as promising biomarkers for tumor metastasis and potential therapeutic strategies for pancreatic cancer.

Keywords